ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,841 to 1,860 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention vs Control: Healthcare Utilization920 of 2,353

1,080 of 2,479

-4.5 points

-7.2 to -1.7

4,832NCT03207776

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Intervention vs Control: Patient-centric (Protocol Defined) Readmission Rate659 of 2,353

753 of 2,479

-2.4 points

-4.9 to 0.2

4,832NCT03207776

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: serious adverse events1,004 of 2,411

1,052 of 2,417

-1.9 points

-4.7 to 0.9

4,828NCT00553410

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

Arm B (Short Term Storage) vs Standard of Care (Long Term Storage): deaths from any cause687 of 2,410

678 of 2,414

0.4 points

-2.1 to 3.0

4,824NCT01638416

Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial

Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events504 of 2,412

495 of 2,405

0.3 points

-2.0 to 2.6

4,817NCT00439777

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause205 of 2,400

247 of 2,404

-1.7 points

-3.4 to -0.1

4,804NCT01358877

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

LCZ696 vs Valsartan: All-cause Mortality342 of 2,407

349 of 2,389

-0.4 points

-2.4 to 1.6

4,796NCT01920711

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Any Coronary Revascularization278 of 2,391

288 of 2,395

-0.4 points

-2.2 to 1.4

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Coronary Revascularization190 of 2,391

205 of 2,395

-0.6 points

-2.2 to 0.9

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Events170 of 2,391

167 of 2,395

0.1 points

-1.3 to 1.6

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization201 of 2,391

207 of 2,395

-0.2 points

-1.8 to 1.3

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality344 of 2,391

345 of 2,395

-0.0 points

-2.0 to 2.0

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Hospitalization for Congestive Heart Failure48 of 2,391

53 of 2,395

-0.2 points

-1.0 to 0.6

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With All-cause Mortality96 of 2,391

83 of 2,395

0.5 points

-0.5 to 1.6

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: deaths from any cause96 of 2,391

83 of 2,395

0.5 points

-0.5 to 1.6

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: Number of Subjects With Hospitalization for Unstable Angina That Led to Unplanned Coronary Revascularization41 of 2,391

50 of 2,395

-0.4 points

-1.2 to 0.4

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Methotrexate vs Placebo: serious adverse events569 of 2,391

549 of 2,395

0.9 points

-1.5 to 3.3

4,786NCT01594333

Cardiovascular Inflammation Reduction Trial

Interactive Two-way SMS Dialogue vs No SMS Control: Exclusive Breastfeeding2,190 of 2,386

2,217 of 2,396

-0.7 points

-2.3 to 0.8

4,782NCT04598165

Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support

Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. New Microalbuminuria276 of 2,372

363 of 2,403

-3.5 points

-5.4 to -1.5

4,775NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

N-Acetylcysteine (NAC) vs Placebo: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.115 of 2,391

112 of 2,381

0.1 points

-1.1 to 1.3

4,772NCT01467466

Prevention of Serious Adverse Events Following Angiography

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=93

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03207776-ce316c8b",
        "title": "Intervention vs Control: Healthcare Utilization",
        "summary": "920 of 2353 against 1080 of 2479; risk difference -4.5 points, 95% interval -7.2 to -1.7; NCT03207776, An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD",
        "record": "/library/comparisons/NCT03207776-ce316c8b",
        "nct_id": "NCT03207776",
        "kind": "outcome",
        "participants": 4832,
        "risk_difference": {
          "value": -0.044669314892783196,
          "lower": -0.07233647766671894,
          "upper": -0.016889691388850114
        },
        "group_1": "920 of 2,353",
        "group_2": "1,080 of 2,479",
        "difference": "-4.5 points",
        "interval": "-7.2 to -1.7",
        "trial_title": "An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD"
      },
      {
        "id": "NCT03207776-cfcd3162",
        "title": "Intervention vs Control: Patient-centric (Protocol Defined) Readmission Rate",
        "summary": "659 of 2353 against 753 of 2479; risk difference -2.4 points, 95% interval -4.9 to 0.2; NCT03207776, An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD",
        "record": "/library/comparisons/NCT03207776-cfcd3162",
        "nct_id": "NCT03207776",
        "kind": "outcome",
        "participants": 4832,
        "risk_difference": {
          "value": -0.02368351440669414,
          "lower": -0.049262433472598496,
          "upper": 0.0019739846586620535
        },
        "group_1": "659 of 2,353",
        "group_2": "753 of 2,479",
        "difference": "-2.4 points",
        "interval": "-4.9 to 0.2",
        "trial_title": "An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=94",
  "request_id": "Vl1fvgGHf2EcdqGH"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?